Список проголосовавших за комментарий " GenVec downgraded to Neutral at Rodman & Renshaw; tgt lowered to $7 (6.57)Rodman & Renshaw downgrades GNVC to Neutral from Buy and lowers their tgt to $7 from $15. Yesterday, Intrexon (<strong>XON</strong>; not rated) and GenVec announced the agreement for Intrexon to acquire GenVec. Pursuant to the agreement, GenVec stockholders would receive 0.297 of a share of Intrexon common stock upon the closing of the transaction in exchange for each share of GenVec common stock. The exchange ratio represents $7.00 of value per share of Genvec's common stock. GenVec stockholders would also receive a right to contingent consideration equal to 50% of any milestone or royalty payments received within 36 months after the closing of the transaction under GenVec's license agreement with Novartis (<strong>NVS</strong>; not rated). Mgmt expects the deal to close in 2Q17. <strong>Firm feels, though the approximate $15M valuation of GenVec's AdenoVerse technology platform in this deal may undervalue the potential of the company's CGF166 in treating hearing loss, it is nevertheless a decent offer at the present time considering the relative lack of visibility in the clinical trial status and development time frame of the ongoing Phase 1/2 study of CGF166 from Novartis.</strong>"